Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Panacos Pharmaceuticals

1992 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
PANC STOCK SYMBOL
Description

Developer of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company's discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion.

Website
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Drug Discovery
Primary Office
  • 134 Coolidge Avenue
  • Watertown, MA 02472
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Panacos Pharmaceuticals’s full profile, request a free trial.

Panacos Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
3.17K

Panacos Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2008
FY 2007
31-Dec-2007
FY 2006
31-Dec-2006
FY 2005
31-Dec-2005
Enterprise Value (176) 3,498 137,430 328,494
Revenue 99 180 284 1,049
Net Income (35,755) (37,459) (38,110) (59,078)
Total Assets 29,738 55,710 65,653 91,571
Total Debt 18,206 19,311 361 213
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Panacos Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Panacos Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Panacos Pharmaceuticals Executive Team (4)

Name Title Board
Seat
Contact
Info
John Barr President & Chief Executive Officer

3 Former Executives

You’re viewing 1 of 4 executives. Get the full list »